Skip to the answer

Decitabine and Cedazuridine Uses, Dosage, Side Effects and Interactions

Brand name
Inqovi

Inqovi was the first decitabine and cedazuridine product the FDA approved, in July 2020. No generic is listed as tablets.

First generic of Inqovi: our estimate, February 2034

Decitabine and cedazuridine is an oral combination cancer medicine used for certain bone marrow disorders (myelodysplastic syndromes, including chronic myelomonocytic leukemia) and, with venetoclax, for newly diagnosed acute myeloid leukemia in some adults.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Decitabine and CedazuridineType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Decitabine and Cedazuridine in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Inqovi pairs decitabine, which can help blood cells mature more normally, with cedazuridine, which stops the gut and liver breaking decitabine down, so this specialist cancer drug works as a tablet rather than an infusion for myelodysplastic syndromes (bone marrow disorders that make too few healthy blood cells), including CMML, and, with venetoclax, newly diagnosed acute myeloid leukemia; it has been on the market since about 2020, with no generic. Most people manage it, though tiredness, constipation and nausea are common and blood counts drop each cycle. Call your care team right away for fever, chills or unusual bleeding, since low counts can cause serious, sometimes fatal infections.

Key Takeaways From the HelloPharmacist Team

  • Take it once daily for the first 5 days of each 28-day cycle, with no food for 2 hours before and after.
  • Expect blood tests before every cycle, and a low count can mean a delayed cycle or fewer dosing days.
  • Take any anti-nausea medicine your prescriber suggests before each dose, and call right away if you vomit or cannot keep doses down.
  • Swallow the tablets whole without cutting or crushing, and follow the special handling and disposal instructions, since this is a hazardous drug.

How we write and review this content: our editorial policy

Decitabine and Cedazuridine by the Numbers

Strengths
1
in one form
Makers and packagers
1
Earliest FDA record
2020
Rank by Medicaid prescriptions
#1,580 of 1,682 drugs
More prescriptions than 6% of the 1,682 drugs we measure
100 prescriptions, Q1–Q4 2025

Patient Information Guide for Decitabine and Cedazuridine

What It’s Used For

Decitabine and cedazuridine is used for these conditions in adults:

  • Myelodysplastic syndromes (MDS): Inqovi treats previously treated and untreated MDS, including chronic myelomonocytic leukemia (CMML).
  • Acute myeloid leukemia (AML): Inqovi is used with venetoclax for newly diagnosed AML in adults 75 or older, or those with conditions that rule out intensive induction chemotherapy.

How It Works

Decitabine is built into the DNA of cells and blocks an enzyme called DNA methyltransferase. This lowers DNA methylation, which may help restore normal control of how blood cells mature and multiply. In fast-dividing cells, it can also be toxic and cause cell death.

Cedazuridine blocks cytidine deaminase, an enzyme in the gut and liver that breaks down decitabine. This lets decitabine work when swallowed.

Drug Class

Drug Class

  • Nucleoside Metabolic Inhibitor from decitabine
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Decitabine and Cedazuridine has two active ingredients, so each class says which one it comes from.

Drug Class

Established Pharmacologic Class (EPC)
  • Nucleoside Metabolic Inhibitor from decitabine

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Nucleic Acid Synthesis Inhibitors from decitabine

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Decitabine and Cedazuridine in the FDA’s index.

From our Patient Information GuideDecitabine is built into the DNA of cells and blocks an enzyme called DNA methyltransferase. This lowers DNA methylation, which may help restore normal control of how blood cells mature and multiply. In fast-dividing cells, it can also be toxic and cause cell death. Cedazuridine blocks cytidine deaminase, an enzyme in the gut and liver that breaks down decitabine. Read How Decitabine and Cedazuridine Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Decitabine and Cedazuridine in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Pyrimidine analogues from decitabine

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Inqovi is a tablet taken by mouth once daily for 5 days of each 28-day cycle.

  • Take it on an empty stomach, 2 hours before or after eating.
  • Swallow whole, at about the same time each day.
  • With venetoclax, take Inqovi 2 hours before or after it.
  • Missed a dose by less than 12 hours? Take it as soon as possible, then go back to your normal schedule. Your treatment period is extended by a day for each missed dose.
  • If you vomit after a dose, do not take an extra one. Take your next scheduled dose.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)

For adults · Recommended dose
Usual dose 1 tablet (35 mg decitabine and 100 mg cedazuridine) once a day
  • 1 tablet (containing 35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle for a minimum of 4 cycles until disease progression or unacceptable toxicity

Good to know

Take on an empty stomach at least 2 hours before or 2 hours after eating

Newly diagnosed acute myeloid leukemia (AML)

Usual dose 1 tablet (35 mg decitabine and 100 mg cedazuridine) once a day
  • 1 tablet (containing 35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle until disease progression or unacceptable toxicity

Good to know

Match Day 1 of Inqovi dosing with Day 1 of venetoclax dosing; take Inqovi 2 hours before or 2 hours after venetoclax

Special Situations

If side effects need a lower dose

Your doctor decides whether to lower your dose for side effects. Never change your dose on your own.

  • MDS or CMML, monotherapy, first dose reduction for myelosuppression

    1 tablet orally once daily on Days 1 through 4

  • MDS or CMML, monotherapy, second dose reduction for myelosuppression

    1 tablet orally once daily on Days 1 through 3

  • MDS or CMML, monotherapy, third dose reduction for myelosuppression

    1 tablet orally once daily on Days 1, 3 and 5

  • AML, in combination with venetoclax, first dose reduction

    1 tablet orally once daily on Days 1, 2 and 3

  • AML, in combination with venetoclax, second dose reduction

    1 tablet orally once daily on Days 1, 3 and 5

  • AML, in combination with venetoclax, third dose reduction

    1 tablet orally once daily on Days 1 and 2

See the Full Dosing Instructions on DailyMed →

Side Effects

Common side effects include:

Common side effects

  • Tiredness
  • Constipation
  • Bleeding or easy bruising
  • Muscle and joint pain
  • Mouth sores or soreness
  • Nausea and diarrhea
  • Shortness of breath
  • Low white blood cells, platelets and red blood cells (seen on blood tests)
  • Shortness of breath, cough
  • Rash, dizziness, headache
  • Swelling and decreased appetite

When to get medical help

  • Call your doctor right away for fever, chills or other signs of infection. Severe infections such as pneumonia and sepsis (a life-threatening blood infection) can be fatal.
  • Tell your doctor about unusual bleeding or bruising, or feeling very weak or short of breath. These can signal low blood counts.
  • Let your care team know right away if you vomit, have severe diarrhea, or can't keep your medicine down.
  • Tell your doctor right away if you become pregnant or think you might be.

Warnings and Precautions

  • Severe myelosuppression: low blood counts can lead to fatal infections and bleeding. Blood counts are checked before treatment and before each cycle.
  • Serious infections: pneumonia and sepsis can occur, and some cases were fatal.
  • Fetal harm: Inqovi can harm an unborn baby.
  • Hazardous drug: special handling and disposal procedures apply.

Interactions

Few interactions are described, but one matters:

  • Drugs broken down by cytidine deaminase: avoid combining, because cedazuridine can raise their levels and toxicity.
  • Venetoclax: used together for AML. Take 2 hours apart.
  • Food: it lowers decitabine absorption, so take on an empty stomach.

Interactions Listed in the FDA-Approved Label

From the Decitabine and Cedazuridine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Drugs metabolized by cytidine deaminase (CDA)
    What happensCedazuridine inhibits the CDA enzyme, so coadministration may increase systemic exposure with potential for increased toxicity of these drugs.
    What to doAvoid coadministration of INQOVI with drugs that are metabolized by CDA.
Read the label’s full interactions text

7 DRUG INTERACTIONS Drugs Metabolized by Cytidine Deaminase: Avoid coadministration with INQOVI. 7.1 Effects of INQOVI on Other Drugs Drugs Metabolized by Cytidine Deaminase Cedazuridine is an inhibitor of the cytidine deaminase (CDA) enzyme. Coadministration of INQOVI with drugs that are metabolized by CDA may result in increased systemic exposure with potential for increased toxicity of these drugs. Avoid coadministration of INQOVI with drugs that are metabolized by CDA.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Tell your doctor if you are pregnant or planning pregnancy. A pregnancy test is needed before starting.
  • Use effective contraception: 6 months after the last dose for females, 3 months for males with female partners.
  • Do not breastfeed during treatment and for 2 weeks after the last dose.
  • Inqovi may impair male fertility.
  • Safety in children has not been established.
  • Tell your doctor about kidney problems. It has not been studied in severe kidney disease.
  • Tell your doctor about any current infection.

Half-Life and How Your Body Processes It

Cedazuridine raises how much decitabine your body absorbs from a tablet. Over 5 days, decitabine exposure was about the same as with intravenous decitabine. A high-fat meal lowers decitabine absorption. Decitabine is mainly broken down by cytidine deaminase and has a half-life of about 1.5 hours. Cedazuridine's half-life is about 6.7 hours and it leaves the body through urine and stool.

Storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Supplements and Herbs That Interact With Decitabine and Cedazuridine

From the licensed clinical database we use, rolled up per supplement, most serious first.

17 supplements and herbal products have documented interactions with Decitabine and Cedazuridine in the licensed clinical database we use.

Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.

  • 1Major
  • 7Moderate
  • 9Minor

See the other 9

Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Decitabine and Cedazuridine: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Decitabine and Cedazuridine — the kind of thing our pharmacy team would talk through with you at the counter.

What is Inqovi used for?

Inqovi treats myelodysplastic syndromes, including CMML, in adults. It is also used with venetoclax for newly diagnosed acute myeloid leukemia in adults 75 or older, or those who can't have intensive chemotherapy.

How do I take Inqovi?

Take one tablet by mouth once a day for 5 days of each 28-day cycle. Take it on an empty stomach, at least 2 hours before or after eating. Swallow it whole. Do not cut, crush or chew it.

What happens if I miss a dose of Inqovi?

If it's within 12 hours of your usual time, take it as soon as you can, then go back to your normal schedule. Your dosing period is extended by one day for each missed dose. If you vomit after a dose, don't take another. Just take your next scheduled one.

What side effects should I call my doctor about?

Call right away for fever, chills or other signs of infection, or for unusual bleeding or bruising. Inqovi can lower your blood counts, and serious infections can happen. Tiredness, constipation, nausea and mouth sores are common and worth mentioning.

Is Inqovi safe during pregnancy or breastfeeding?

No. It can harm an unborn baby, so a pregnancy test is needed first. Use effective contraception during treatment and for 6 months afterward if you can become pregnant, or 3 months if you're a male with a partner who can. Don't breastfeed during treatment and for 2 weeks after your last dose.

Can I take Inqovi with other medicines?

Avoid drugs broken down by cytidine deaminase, because Inqovi can raise their levels. If you take venetoclax too, take the two 2 hours apart. Always tell your pharmacist about everything you take.

Is decitabine and cedazuridine available over the counter?

No. Decitabine and cedazuridine is a prescription medicine: every decitabine and cedazuridine product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was decitabine and cedazuridine first available?

The earliest FDA record we hold for decitabine and cedazuridine is from 2020: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when decitabine and cedazuridine was first used.

What is the brand name of decitabine and cedazuridine?

Decitabine and cedazuridine is the generic name. Its brand name is Inqovi.

What is the generic name of Inqovi?

The generic name of Inqovi is decitabine and cedazuridine. A generic name is the name of the active ingredients, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is decitabine and cedazuridine?

Decitabine and cedazuridine belongs to the drug class Nucleoside Metabolic Inhibitor, its established pharmacologic class on the FDA label. The FDA also groups it by how it works: Nucleic Acid Synthesis Inhibitor.

What strengths does decitabine and cedazuridine come in?

Decitabine and cedazuridine is listed in the FDA's National Drug Code Directory in these forms and strengths. Tablet (by mouth): 35 mg/100 mg. A listing does not mean every pharmacy stocks every strength.

How much does decitabine and cedazuridine cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, state Medicaid programs paid an average of $1,786.02 per CEDAZURIDINE 100 mg/1; DECITABINE 35 mg tablet of brand-name Inqovi over the four quarters through Q1 2026 (CMS's State Drug Utilization Data), before the rebates drug makers pay Medicaid. CMS's weekly pharmacy survey (NADAC) has no price for it, and Medicaid's figure is what a program paid, not the price at the counter. The pharmacy prices section of this page lists every strength priced.

Where can I read the decitabine and cedazuridine prescribing information (package insert)?

The full FDA-approved prescribing information for decitabine and cedazuridine, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Taiho Pharmaceutical Co., Ltd.'s, revised May 25, 2026, and links to it on DailyMed.

Can you crush decitabine and cedazuridine?

Some forms of decitabine and cedazuridine are on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: Decitabine-cedazuridine (tablet); Inqovi (tablet). Crushing or splitting a hazardous drug can expose whoever handles it. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Decitabine and Cedazuridine

Skip the scrolling. Ask in your own words and get an answer from Decitabine and Cedazuridine’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Decitabine and Cedazuridine’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Decitabine and Cedazuridine on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, usually within a day.
Detailed Data & References for Decitabine and Cedazuridine Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Decitabine and Cedazuridine Forms and Strengths (How It Comes)

Decitabine and Cedazuridine comes in 1 dose form, the tablet. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Decitabine and Cedazuridine inactive ingredients by manufacturer.

Tablet

By mouth
Brands Inqovi (the first brand, 2020)
How this form is used
What it may be used for
  • Inqovi is used in adults with myelodysplastic syndromes, including chronic myelomonocytic leukemia.
  • Inqovi is used with venetoclax for newly diagnosed acute myeloid leukemia in adults 75 or older, or those who can't have intensive chemotherapy.
Important instructions
  • Inqovi is taken once daily on Days 1 through 5 of each 28-day cycle, on an empty stomach.
  • Swallow Inqovi tablets whole. Do not cut, crush or chew them.
  • Inqovi should not be swapped for intravenous decitabine within a cycle.
Available strengths 1 strength
1 FDA-listed product record ⓘ

Decitabine and Cedazuridine on the U.S. Market: Products, Makers and Brands

How Decitabine and Cedazuridine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 1 Decitabine and Cedazuridine product record with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2020. The one brand name in the directory today is Inqovi; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
1
FDA-listed product records ⓘ
2020
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Unfinished tablet (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

How Widely Decitabine and Cedazuridine Is Used (Medicaid Data)

How many Decitabine and Cedazuridine prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

100
Medicaid prescriptions filled (Q1–Q4 2025)
$866,444 paid by Medicaid, before rebates

How commonly is Decitabine and Cedazuridine prescribed? Of the 1,682 medications we measure, Decitabine and Cedazuridine ranks #1,580 by Medicaid prescriptions — more than 6% of them.

Where Decitabine and Cedazuridine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Decitabine and Cedazuridine product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

Other Decitabine and Cedazuridine products: packs and listings not matched to one strength and form

100 Medicaid prescriptions (Q1–Q4 2025) 100% of Decitabine and Cedazuridine prescriptions shown $866,444 paid by Medicaid, before rebates ≈ $8,664 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims.

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 1 of the 2 listed Decitabine and Cedazuridine NDCs had Medicaid claims.

Compare Decitabine and Cedazuridine Products

A representative set of FDA-listed product records for Decitabine and Cedazuridine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Tablet
CEDAZURIDINE 100 mg/1; DECITABINE 35 mg Oral Taiho Pharmaceutical Co., Ltd. NDA View NDC →

Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Decitabine and Cedazuridine NDCs →

Decitabine and Cedazuridine Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Decitabine and Cedazuridine recalls since July 2021.

✅No Decitabine and Cedazuridine recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

What Medicaid Pays for Decitabine and Cedazuridine

CMS’s weekly pharmacy survey (NADAC) has no price for Decitabine and Cedazuridine, so here is what state Medicaid programs paid for it over the four quarters through Q1 2026, before rebates. It is not your price at the counter.

FormStrengthVersion What Medicaid paid
Tablet · Oral CEDAZURIDINE 100 mg/1; DECITABINE 35 mg Inqovi (brand) $1,786.02 per tablet NDC details & Medicaid use
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS State Drug Utilization Data, total paid divided by units paid for across every state, for each strength’s packages.

Decitabine and Cedazuridine Brand Names

Decitabine and Cedazuridine has one brand name on record: Inqovi. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Inqovi the first brand, 2020

Who Makes Decitabine and Cedazuridine: Manufacturers and Labelers

One company lists Decitabine and Cedazuridine products with the FDA. By number of product records, the largest are Taiho Pharmaceutical Co., Ltd.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Taiho Pharmaceutical Co., Ltd. 1

Sources for This Decitabine and Cedazuridine Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated May 25, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Decitabine and Cedazuridine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Finished products in the current FDA directory
1
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Taiho Pharmaceutical Co., Ltd.
Linked label effective
May 25, 2026
Composite sections available
22
Linked SPL Set ID
91a0f80b-f865-4d06-a40d-4d148d99ee71
Linked SPL Document ID
130350a1-2b88-4253-99ea-9fbc0d066ea7
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Taiho Pharmaceutical Co., Ltd. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →